Dobutamine is a cardiac inotrope useful in the acute treatment of congestive heart failure. Dobutamine improves cardiac output, decreases pulmonary wedge pressure, and decreases total systemic vascular resistance with little effect on heart rate or systemic arterial pressure. Clinical benefit has been observed to continue for weeks to months following the discontinuation of dobutamine. In addition, tolerance to dobutamine has been observed when infusions last 72 hours or longer. This has led investigators to study the effectiveness of chronic intermittent infusions of dobutamine. Studies utilizing dobutamine doses ranging from 1.5 to 15 μg/kg/min for 4–48 h/wk have shown sustained clinical and hemodynamic improvement in patients suffering from congestive heart failure The mechanism by which dobutamine creates this effect is not entirely known; however, studies suggest dobutamine exerts a physical conditioning effect similar to exercise. Dobutamine infusions have also been associated with morphological and metabolic changes in myocardial tissue consistent with improved myocardial structure and function. The intermittent use of dobutamine may be beneficial in the chronic treatment of congestive heart failure in patients who fail to respond to conventional therapy.
FowlerMBAldermanELOesterleSNDobutamine and dopamine after cardiac surgery: greater augmentation of myocardial blood flow with dobutamine. Circulation1984; 70 (suppl I): 1103–11.
2.
GillespieTAAmbosHDSobelBERobertsR. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol1977; 39: 588–94.
3.
BenderskyRChatterjeeKParmleyWWBrundageBHPortsTA. Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. Am J Cardiol1981; 48: 554–8.
4.
LeierCVWebelJBushCA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation1977; 56: 468–72.
5.
UnverferthDVMagorienRDLewisRPLeierCV. Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J1980; 100: 622–30.
6.
LiangCShermanLGDohertyJUWellingtonKLeeVWHoodWB. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation1984; 69: 113–9.
7.
UnverferthDVBlanfordMKatesRELeierCV. Tolerance to dobutamine after a 72 hour continuous infusion. Am J Med1980; 69: 262–6.
8.
ApplefeldMMNewmanKAGroveWRIntermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol1983; 51: 455–8.
9.
LeierCVHussPLewisRPUnverferthDV. Drug-induced conditioning in congestive heart failure. Circulation1982; 65: 1382–7.
10.
RoffmanDSApplefeldMMGroveWRIntermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure. Clin Pharm1985; 4: 195–9.
11.
HodgsonJMAjaMSorkinRP. Intermittent ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol1984; 53: 375–6.
12.
BergerMMcSherryCK. Outpatient dobutamine infusion using a totally implantable infusion pump for refractory congestive heart failure. Chest1985; 88: 295–6.
13.
JewittDBirkheadJMitchellADolleryC. Clinical cardiovascular pharmacology of dobutamine: a selective inotropic catecholamine. Lancet1974; 2: 363–7.
14.
BeregovichJBianchiCD'AngeloRDiazRRublerS. Haemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure. Br Heart J1975; 37: 629–34.
15.
AkhtarNMikulicECohnJNChaudhryMH. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol1975; 36: 202–5.
16.
TuttleRRMillsJ. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res1975; 36: 185–96.
17.
RobieNWNutterDOMoodyCMcNayJL. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res1974; 34: 663–71.
18.
RuffoloRRSpradlinTAPollockGDWaddellJEMurphyPJ. Alpha and beta adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther1981; 219: 447–52.
19.
RuffoloRRYadenEL. Vascular effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther1982; 224: 46–50.
20.
KenakinTP. An in vitro quantitative analysis of the alpha adrenoceptor partial agonist activity of dobutamine and its relevance to inotropic selectivity. J Pharmacol Exp Ther1981; 216: 210–9.
21.
RuffoloRRMessickK. Systemic hemodynamic effects of dopamine, (±) — dobutamine and the (+) — and (−) — enantiomers of dobutamine in anesthetized normotensive rats. Eur J Pharmacol1985; 109: 173–81.
22.
RuffoloRRMessickK. Effects of dopamine, (±) — dobutamine and the (+) — and (−) — enantiomers of dobutamine on cardiac function in the pithed rats. J Pharmacol Exp Ther1985; 235: 558–65.
23.
RuffoloRRMessickK. Inotropic selectivity of dobutamine enantiomers in the pithed rat. J Pharmacol Exp Ther1985; 235: 344–8.
24.
RuffoloRR. Distribution and function of peripheral alphaadrenoceptors in the cardiovascular system. Pharmacol Biochem Behav1985; 22: 827–33.
25.
VatnerSFMcRitchieRJBraunwaldE. Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs. J Clin Invest1974; 53: 1265–73.
26.
OzakiNKawakitaSTodaN. Effects of dobutamine on isolated canine cerebral, coronary, mesenteric, and renal arteries. J Cardiovasc Pharmacol1982; 4: 456–61.
27.
LumleyPBroadleyKJLevyGP. Analysis of the inotropic: chronotropic selectivity of dobutamine and dopamine in anaesthetized dogs and guinea pig isolated atria. Cardiovasc Res1977; 11: 17–25.
28.
MurphyPJWilliamsTLKauDLK. Disposition of dobutamine in the dog. J Pharmacol Exp Ther1976; 199: 423–31.
29.
LeierCVUnverferthDV. Dobutamine. Ann Intern Med1983; 99: 490–6.
30.
KatesRELeierCV. Dobutamine pharmacokinetics in severe heart failure. Clin Pharmacol Ther1978; 24: 537–41.
31.
LeierCVUnverferthDVKatesRE. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med1979; 66: 238–42.
32.
LeierCVHebanPTHussPBushCALewisRP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation1978; 58: 466–75.
33.
UnverferthDVMagorienRDAltschuldRKolibashAJLewisRPLeierCV. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy. Am Heart J1983; 106: 29–34.
34.
MagorienRDUnverferthDVBrownGPLeierCV. Dobutamine and hydralazine: comparative influences of positive inotropy and vasodilation on coronary blood flow and myocardial energetics in nonischemic congestive heart failure. J Am Coll Cardiol1983; 1: 499–505.
BianchiCDiazRGonzalesCBeregovichJ. Effects of dobutamine on atrioventricular conduction. Am Heart J1975; 90: 474–8.
37.
MasoniAAlboniPMalacarneCCodecaL. Effects of dobutamine on electrophysiological properties of the specialized conduction system in man. J Electrocardiol1979; 12: 361–70.
LefkowitzRJCaronMGStilesGL. Mechanism of membranereceptor regulation: biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med1984; 310: 1570–9.
40.
MorrisHGRusnakSABarzensK. Leukocyte cyclic adenosine monophosphate in asthmatic children: effects of adrenergic therapy. Clin Pharmacol Ther1977; 22: 352–7.
LiangCTuttleRRHoodWBGavrasH. Conditioning effects of chronic infusions of dobutamine: comparison with exercise training. J Clin Invest1979; 64: 613–9.
43.
SullivanMJBinkleyPFUnverferthDVPrevention of bedrest-induced physical deconditioning by daily dobutamine infusions. J Clin Invest1985; 76: 1632–42.
44.
UnverferthDVLeierCVMagorienRDImprovement of human myocardial mitochondria after dobutamine: a quantitative ultrastructural study. J Pharmacol Exp Ther1980; 215: 527–32.
45.
JenningsRBShenACHillMLGanoteCEHerdsonPB. Mitochondrial matrix densities in myocardial ischemia and autolysis. Exp Mol Pathol1978; 29: 55–65.
46.
JenningsRBGanoteCE. Mitochondrial structure and function in acute myocardial ischemic injury. Circ Res1976; 38 (suppl 1): 80–9.
47.
ColganJALazarusMLSachsHG. Post-natal development of the normal and cardiomyopathic Syrian hamster heart: a quantitative electron microscopic study. J Mol Cell Cardiol1978: 10: 43–54.
